A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.
Eribulin mesylate
HER2+ breast cancer
Pertuzumab
Trastuzumab
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
29
03
2021
accepted:
07
07
2021
pubmed:
25
7
2021
medline:
14
8
2021
entrez:
24
7
2021
Statut:
ppublish
Résumé
There are limited data on trastuzumab-pertuzumab (HP)-based treatments beyond the first-line, HER2+ metastatic breast cancer (MBC) setting. We conducted a phase II study of eribulin mesylate, which extends survival in MBC, with HP in patients with previously treated HER2+ MBC to evaluate efficacy, toxicity, and genomic alterations driving therapeutic response. After a run-in phase for eribulin dosing, two cohorts were enrolled (Cohort A-no prior pertuzumab; Cohort B-prior pertuzumab). All patients received eribulin 1.4 mg/m The six-patient run-in established a dose of eribulin 1.4 mg/m Eribulin-HP had manageable toxicity and modest clinical activity in patients without prior pertuzumab exposure. This study provides a preliminary landscape of somatic alterations in this patient cohort. Our data add to the literature on how genomic alterations may predict for therapy response/resistance, as we work to individualize choices in a quickly evolving HER2+ MBC treatment landscape. www.clinicaltrials.gov , NCT01912963. Registered 24 July 2013.
Identifiants
pubmed: 34302589
doi: 10.1007/s10549-021-06329-x
pii: 10.1007/s10549-021-06329-x
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Furans
0
Ketones
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
pertuzumab
K16AIQ8CTM
eribulin
LR24G6354G
Trastuzumab
P188ANX8CK
Banques de données
ClinicalTrials.gov
['NCT01912963']
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
411-423Subventions
Organisme : American Cancer Society
ID : MRSG-14-240-01-CPPB
Organisme : Susan G. Komen
ID : CCR14298143
Pays : United States
Organisme : Susan G. Komen
ID : CCRCR18552788
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734
pubmed: 25693012
pmcid: 5584549
doi: 10.1056/NEJMoa1413513
Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Poznak CHV, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NYR, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU (2016) Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol 34(9):945–952
pubmed: 5070554
pmcid: 5070554
doi: 10.1200/JCO.2015.63.0343
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791
pubmed: 23020162
pmcid: 5125250
doi: 10.1056/NEJMoa1209124
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743
pubmed: 17192538
doi: 10.1056/NEJMoa064320
pmcid: 17192538
Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Poznak CHV, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O’Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU (2019) TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol 37(13):1081–1089
pubmed: 30860945
pmcid: 6494354
doi: 10.1200/JCO.18.01511
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382(7):597–609
pubmed: 31825569
doi: 10.1056/NEJMoa1914609
pmcid: 31825569
Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im S-A, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I (2020) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382(7):610–621
pubmed: 31825192
doi: 10.1056/NEJMoa1914510
pmcid: 31825192
Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J (2012) Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(14):1594–1600
pubmed: 22393084
doi: 10.1200/JCO.2011.37.4207
pmcid: 22393084
Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L (2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9(1):16–32
pubmed: 22124364
doi: 10.1038/nrclinonc.2011.177
pmcid: 22124364
Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, Marschner N, Gluz O, Schrader I, Heinrich G, Untch M, Jackisch C (2013) HER2 dimerization inhibitor pertuzumab—mode of action and clinical data in breast cancer. Breast Care (Basel) 8(1):49–55
doi: 10.1159/000346837
Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119
pubmed: 22149875
doi: 10.1056/NEJMoa1113216
pmcid: 22149875
Dybdal-Hargreaves NF, Risinger AL, Mooberry SL (2015) Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res 21(11):2445–2452
pubmed: 25838395
pmcid: 4812567
doi: 10.1158/1078-0432.CCR-14-3252
Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, DaCosta NA, Chuang E, Smith J, O’Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) Phase II study of eribulin mesylate, a halichondrin b analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27(18):2954–2961
pubmed: 19349550
doi: 10.1200/JCO.2008.17.7618
pmcid: 19349550
Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28(25):3922–3928
pubmed: 20679609
doi: 10.1200/JCO.2009.25.8467
pmcid: 20679609
Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914–923
pubmed: 21376385
doi: 10.1016/S0140-6736(11)60070-6
pmcid: 21376385
Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA (2010) Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 10(2):160–163
pubmed: 20299316
doi: 10.3816/CBC.2010.n.023
pmcid: 20299316
Gale M, Li Y, Cao J, Liu ZZ, Holmbeck MA, Zhang M, Lang SM, Wu L, Do Carmo M, Gupta S, Aoshima KA-O, DiGiovanna MP, Stern DA-O, Rimm DL, Shadel GS, Chen X, Yan QA-OX (2020) Acquired resistance to HER2-targeted therapies creates vulnerability to ATP synthase inhibition. Cancer Res 80(3):524–535
pubmed: 31690671
doi: 10.1158/0008-5472.CAN-18-3985
pmcid: 31690671
Pohlmann PR, Mayer IA, Mernaugh R (2009) Resistance to trastuzumab in breast cancer. Clin Cancer Res 15(24):7479–7491
pubmed: 20008848
pmcid: 3471537
doi: 10.1158/1078-0432.CCR-09-0636
O’Shaughnessy J, Huggins-Puhalla SL, Wilks S, Brufsky A, Schwartzberg LS, Berrak E, Song JX, Cox D, Vahdat LT (2014) Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): results from a phase 2, single-arm, multicenter study. J Clin Oncol 32(26 Suppl.):139–139
doi: 10.1200/jco.2014.32.26_suppl.139
Wilks S, Puhalla S, O’Shaughnessy J, Schwartzberg L, Berrak E, Song J, Cox D, Vahdat L (2014) Phase 2, Multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer 14(6):405–412
pubmed: 25024001
doi: 10.1016/j.clbc.2014.04.004
pmcid: 25024001
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 31(31):3997–4013
pubmed: 24101045
doi: 10.1200/JCO.2013.50.9984
pmcid: 24101045
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
doi: 10.1016/j.ejca.2008.10.026
Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang C-Z, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O’Connor EP, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Allen EMV, Winer EP, Lin NU, Nakabayashi M, Taplin M-E, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson M (2017) Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun 8(1):1324
pubmed: 29109393
pmcid: 5673918
doi: 10.1038/s41467-017-00965-y
Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA (2018) The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer 18(11):696–705
pubmed: 30293088
pmcid: 6450507
doi: 10.1038/s41568-018-0060-1
Mao P, Cohen O, Kowalski KJ, Kusiel JG, Buendia-Buendia JE, Cuoco MS, Exman P, Wander SA, Waks AG, Nayar U, Chung J, Freeman S, Rozenblatt-Rosen O, Miller VA, Piccioni F, Root DE, Regev A, Winer EP, Lin NU, Wagle N (2020) Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer. Clin Cancer Res 26(22):5974–5989
pubmed: 32723837
doi: 10.1158/1078-0432.CCR-19-3958
pmcid: 32723837
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, Litchfield LM, Ye XS, Yu C, Jansen VM, Stille JR, Smith PS, Oakley GJ, Chu QS, Batist G, Hughes ME, Kremer JD, Garraway LA, Winer EP, Tolaney SM, Lin NU, Buchanan SG, Wagle N (2020) The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov 10(8):1174–1193
pubmed: 32404308
doi: 10.1158/2159-8290.CD-19-1390
pmcid: 32404308
Belinky F, Nativ N, Stelzer G, Zimmerman S, Stein TI, Safran M, Lancet D (2015) PathCards: multi-source consolidation of human biological pathways. Database 2015:bav006.
Waks AG, Cohen O, Kochupurakkal B, Kim D, Wander SA, Buendia-Buendia J, Helvie K, Matulonis UA, Krop IE, Tolaney SM, Winer EP, D’Andrea AD, Shapiro G, Lin NU, Wagle N (2019) Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC). J Clin Oncol 37(15 Suppl):1085–1085
doi: 10.1200/JCO.2019.37.15_suppl.1085
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale A-L, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DTW, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt ANJ, Valdés-Mas R, van Buuren MM, van’t Veer L, Vincent-Salomon A, Waddell N, Yates LR, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo EA, Shibata T, Pfister SM, Campbell PJ, Stratton MR (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421
pubmed: 3776390
pmcid: 3776390
doi: 10.1038/nature12477
Kim J, Mouw KW, Polak P, Braunstein LZ, Kamburov A, Tiao G, Kwiatkowski DJ, Rosenberg JE, Allen EMV, D’Andrea AD, Getz G (2016) Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet 48(6):600–606
pubmed: 27111033
pmcid: 4936490
doi: 10.1038/ng.3557
Kasar S, Kim J, Improgo R, Tiao G, Polak P, Haradhvala N, Lawrence MS, Kiezun A, Fernandes SM, Bahl S, Sougnez C, Gabriel S, Lander ES, Kim HT, Getz G, Brown JR (2015) Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat Commun 6(1):8866
pubmed: 26638776
doi: 10.1038/ncomms9866
pmcid: 26638776
Tan VYF, Fevotte C (2013) Automatic relevance determination in nonnegative matrix factorization with the /spl beta/-Divergence. IEEE Trans Pattern Anal Mach Intell 35(7):1592–1605
pubmed: 23681989
doi: 10.1109/TPAMI.2012.240
pmcid: 23681989
Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, Damon AL, Shah S, Kim D, Zañudo JGT, Hornick JL, Chen Y-L, Merriam P, Raut CP, Demetri GD, Tine BAV, Lander ES, Golub TR, Wagle N (2020) The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med 26(2):181–187
pubmed: 32042194
doi: 10.1038/s41591-019-0749-z
pmcid: 32042194
Reardon B (2018) Calculate Mutation Burden. https://github.com/brendanreardon/calculate_mutational_burden (accessed 19 Mar 2021)
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang W-W, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Allen EMV, Cherniack AD, Ciriello G, Sander C, Schultz N (2018) Oncogenic signaling pathways in the cancer genome atlas. Cell 173(2):321-337.e310
pubmed: 29625050
pmcid: 6070353
doi: 10.1016/j.cell.2018.03.035
Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J, Sumer SO, Kundra R, Razavi P, Li BT, Reales DN, Socci ND, Jayakumaran G, Zehir A, Benayed R, Arcila ME, Chandarlapaty S, Ladanyi M, Schultz N, Baselga J, Berger MF, Rosen N, Solit DB, Hyman DM, Taylor BS (2017) Accelerating discovery of functional mutant alleles in cancer. Cancer Discov 8(2):174–183
pubmed: 29247016
pmcid: 5809279
doi: 10.1158/2159-8290.CD-17-0321
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N (2017) OncoKB: a precision oncology knowledge base. JCO Precis Oncol 2017:PO.17.00011.
Crowdis J, He MX, Reardon B, Allen EMV (2020) CoMut: visualizing integrated molecular information with comutation plots. Bioinformatics 36(15):4348–4349
pubmed: 32502231
pmcid: 7520041
doi: 10.1093/bioinformatics/btaa554
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau D-A, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Lee RS, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214–218
pubmed: 23770567
pmcid: 3919509
doi: 10.1038/nature12213
Araki K, Fukada I, Yanagi H, Kobayashi K, Shibayama T, Horii R, Takahashi S, Akiyama F, Ohno S, Ito Y (2017) First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer. Breast 35:78–84
pubmed: 28662406
doi: 10.1016/j.breast.2017.06.015
pmcid: 28662406
Tono Y, Ishihara M, Miyahara Y, Tamaru S, Oda H, Yamashita Y, Tawara I, Ikeda H, Shiku H, Mizuno T, Katayama N (2018) Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. Oncotarget 9(19):14909–14921
pubmed: 29599915
pmcid: 5871086
doi: 10.18632/oncotarget.24504
Krop IE, Kim S-B, González-Martı́n A, LoRusso PM, Ferrero J-M, Smitt M, Yu R, Leung ACF, Wildiers H (2014) Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15(7):689–699
pubmed: 24793816
doi: 10.1016/S1470-2045(14)70178-0
pmcid: 24793816
Krop IE, Kim S-B, Martin AG, LoRusso PM, Ferrero J-M, Badovinac-Crnjevic T, Hoersch S, Smitt M, Wildiers H (2017) Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 18(6):743–754
pubmed: 28526538
doi: 10.1016/S1470-2045(17)30313-3
pmcid: 28526538
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück H-J, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S (2011) Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3–05 phase III study in HER2-positive breast cancer. Eur J Cancer 47(15):2273–2281
doi: 10.1016/j.ejca.2011.06.021
Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112(3):533–543
pubmed: 18188694
doi: 10.1007/s10549-007-9885-0
pmcid: 18188694
Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15(9):924–934
pubmed: 20736298
pmcid: 3228041
doi: 10.1634/theoncologist.2009-0181
Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O’Shaughnessy J (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 30(21):2585–2592
pubmed: 22689807
doi: 10.1200/JCO.2011.35.6725
pmcid: 22689807
Inoue K, Ninomiya J, Okubo K, Nakakuma T, Yamada H, Kimizuka K, Higuchi T, Saito T (2019) Abstract P6–17-14: eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical trial for the SBCCSG-36 investigators. Cancer Res. https://doi.org/10.1158/1538-7445.SABCS18-P6-17-14
doi: 10.1158/1538-7445.SABCS18-P6-17-14
pubmed: 31676574
pmcid: 7448227
Urruticoechea A, Rizwanullah M, Im S-A, Sánchez-Ruiz AC, Lang I, Tomasello G, Douthwaite H, Crnjevic TB, Heeson S, Eng-Wong J, Munoz M (2016) PHEREXA: A phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting. J Clin Oncol 34(15 Suppl):504
doi: 10.1200/JCO.2016.34.15_suppl.504
Argolo DFSDTE, Smyth LM, Iyengar NM, Patil S, Norton L, Baselga J, Hudis CA, Dang CT (2015) Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: a retrospective study from single center. J Clin Oncol 33(15 Suppl):616
doi: 10.1200/jco.2015.33.15_suppl.616
Bergin ART, Luen SJ, Savas P, Boolell V, Cho D, Lynch J, Nott L, Stuart-Harris R, Teo LN, Yap SY, Loi S (2019) Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: an Australian case series. Asia Pac J Clin Oncol 15(6):377–382
pubmed: 31321873
doi: 10.1111/ajco.13195
pmcid: 31321873
Iyengar NM, Smyth LM, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, Fornier MN, Goldfarb S, Jhaveri K, Modi S, Troso-Sandoval T, Patil S, Ulaner GA, Jochelson M, Norton L, Hudis CA, Dang CT (2019) Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2–positive metastatic breast cancer. JAMA Netw Open 2(11):e1916211
pubmed: 31774522
pmcid: 6902832
doi: 10.1001/jamanetworkopen.2019.16211
Fedorova O, Daks A, Shuvalov O, Kizenko A, Petukhov A, Gnennaya Y, Barlev N (2020) Attenuation of p53 mutant as an approach for treatment Her2-positive cancer. Cell Death Discov 6(1):100
pubmed: 33083021
pmcid: 7548004
doi: 10.1038/s41420-020-00337-4
Thol F, Kade S, Schlarmann C, Löffeld P, Morgan M, Krauter J, Wlodarski MW, Kölking B, Wichmann M, Görlich K, Göhring G, Bug G, Ottmann O, Niemeyer CM, Hofmann W-K, Schlegelberger B, Ganser A, Heuser M (2012) Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119(15):3578–3584
pubmed: 22389253
doi: 10.1182/blood-2011-12-399337
pmcid: 22389253
Esfahani MS, Lee LJ, Jeon YJ, Flynn RA-O, Stehr H, Hui AB, Ishisoko N, Kildebeck E, Newman AA-O, Bratman SA-O, Porteus MA-O, Chang HA-O, Alizadeh AA-O, Diehn MA-O (2019) Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. Nat Commun 10(1):5712
pubmed: 31836708
pmcid: 6911043
doi: 10.1038/s41467-019-13392-y
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J (2018) The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34(3):427-438.e6
pubmed: 30205045
pmcid: 6327853
doi: 10.1016/j.ccell.2018.08.008
Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70
doi: 10.1038/nature11412
Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG, Buonamici S, Yu L (2018) Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep 23(1):282-296.e4
pubmed: 29617667
pmcid: 5933844
doi: 10.1016/j.celrep.2018.01.088
Zhou Q, Derti A, Ruddy D, Rakiec D, Kao I, Lira M, Gibaja V, Chan H, Yang Y, Min J, Schlabach MR, Stegmeier F (2015) A chemical genetics approach for the functional assessment of novel cancer genes. Cancer Res 75(10):1949–16958
pubmed: 25788694
doi: 10.1158/0008-5472.CAN-14-2930
pmcid: 25788694